Combination of an ASK1 inhibitor and FXR agonist increases efficacy in a mouse model of non-alcoholic steatohepatitisJ.T. Liles, A. Zagorska, D. Hollenback,G.R. Budas,H. Liu,K. Liu,R. Brockett, A. Shauf,D. Tumas,D.G. BreckenridgeJournal of Hepatology（2017）引用 3|浏览13暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
